Abbott Laboratories ABT
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Abbott Laboratories is a large-cap company in the Healthcare sector (Medical Devices), with a market value of $168.7B, based in the USA.
It employs about 122,000 people and has been listed since Jan 13, 1978.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 31.6 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 13% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 17.1 — they expect higher earnings.
The average analyst price target is 120.58, 24% above the current price (their view, not ours).
The stock sits at 32% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 7 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (22 vs 0).
- ✅ Pays a dividend (2.6% a year).
What changed this week
Over the past week the stock fell 3.7% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- Moderna, Illumina lead healthcare gains in September as medtech drags seekingalpha.com · 2026-10-03
- How to Create a Million-Dollar Stock Portfolio finance.yahoo.com · 2026-10-02
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care finance.yahoo.com · 2026-10-02
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike finance.yahoo.com · 2026-10-02
- Abbott Stock And Other Healthcare Dividend Names Built For Supply Chain Shocks finance.yahoo.com · 2026-10-01
- Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.